Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.33 |
| ▸ | NOS3 | P29474 | 5/20 | 0.33 |
| ▸ | NOS1 | P29475 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | BHMT | Q93088 | 1/20 | 0.32 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.32 |
| ▸ | GABRD | O14764 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24213302 | 0.84 | NOS2 (0.33) | NOS2NOS3NOS1KMT2ABHMT | |
| SCHEMBL24125927 | 0.82 | ALDH1A1 (0.37) | NOS2NOS3NOS1KMT2ABHMT | |
| SCHEMBL15080395 | 0.79 | SLC1A3 (0.48) | NOS2NOS3NOS1BHMTBHMT2 | |
| SCHEMBL17164633 | 0.79 | GSR (0.54) | NOS2NOS3NOS1KMT2ABHMT | |
| SCHEMBL10069251 | 0.79 | SLC1A3 (0.48) | NOS2NOS3NOS1BHMTBHMT2 | |
| SCHEMBL12834980 | 0.78 | SLC1A3 (0.34) | NOS2NOS3NOS1GRIK1SLC1A3 | |
| SCHEMBL22381010 | 0.78 | GSR (0.48) | NOS2NOS3NOS1KMT2AMEN1 | |
| SCHEMBL9617324 | 0.78 | GSR (0.48) | NOS2NOS3NOS1KMT2AMEN1 | |
| SCHEMBL28927957 | 0.77 | GABRR1 (0.41) | NOS2NOS3NOS1BHMTBHMT2 | |
| SCHEMBL18739351 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2022-05-17 | — | — | US | disclosed |
| US-11197882-B2 | — | — | 2021-12-14 | — | — | US | disclosed |
| US-11147826-B2 | — | — | 2021-10-19 | — | — | US | disclosed |
| US-20210252033-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-19 | — | — | US | disclosed |
| US-20200276219-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | ENTPD1, NME2, NME1 | NOS2 1898/4885NOS3 1753/4885NOS1 1633/4885 |
| US-11147826-B2 | — | SNRPE, NME2, NME1 | NOS2 1869/4885NOS3 1764/4885NOS1 2176/4885 |
| US-20210252033-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | TYMP, MTAP, DCTD | NOS2 1678/4885NOS3 1614/4885NOS1 1406/4885 |
| US-20200276219-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | NOS2 1898/4885NOS3 1753/4885NOS1 1633/4885 |
| US-11197882-B2 | — | SNRPE, NME2, NME1 | NOS2 1869/4885NOS3 1764/4885NOS1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.